🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Neuroendocrine Carcinoma of Lung

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors NCT05366478Phase 11 site📍 Tianjin Suzhou BlueHorse Therapeutics Co., Ltd. · Tests: Autologous tumor infiltrating lymphocytes (TILs) Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors NCT06840821Phase 1, Phase 21 site📍 Jinan Mainline Biosciences (Shanghai) Co., Ltd · Tests: MB0151 for injection Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites📍 Beijing📍 Beijing📍 Shanghai GV20 Therapeutics · Tests: GV20-0251 A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade NCT07130032Phase 21 site📍 Saint Petersburg EuroCityClinic LLC · Tests: reICB regimen (NSCLC), reICB regimen (melanoma) Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. NCT06440057Phase 1, Phase 21 site📍 Beijing Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZG006 ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort NCT07808164n/a2 sites📍 Hanoi📍 Ho Chi Minh City Tam Anh Research Institute · Tests: IHC analysis for ENPP1, cGAS, and FAP expression A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade NCT07661966NA1 site📍 New York Weill Medical College of Cornell University · Tests: Bright Light Therapy Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC NCT07718243Phase 1, Phase 22 sites📍 Manchester📍 Sutton Institute of Cancer Research, United Kingdom · Tests: Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682Phase 17 sites📍 Frankfurt📍 Heidelberg📍 Tübingen Valo Therapeutics Oy · Tests: PeptiCRAd-1, Cyclophosphamide, Pembrolizumab Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051n/a1 site📍 Austin Natera, Inc. An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors NCT06942143Phase 11 site📍 Guangzhou Guangzhou FineImmune Biotechnology Co., LTD. · Tests: Super1 TCR-T A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases NCT03093909Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Gemcitabine Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) NCT07016230Phase 23 sites📍 Bordeaux📍 Nice📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: Tarlatamab VSV-02 Compassionate Use in Advanced Solid Tumors NCT07260591Phase 11 site📍 Xinxiang The First Affiliated Hospital of Xinxiang Medical College · Tests: VSV-02 Injection Evaluation for NCI Surgery Branch Clinical Research Protocols NCT00001823n/a1 site📍 Bethesda National Cancer Institute (NCI) FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum NCT06393816Phase 231 sites📍 Aix-en-Provence📍 Amiens📍 Angers Centre Leon Berard · Tests: Durvalumab with etoposide and Carboplatin/Cisplatin EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites📍 Los Angeles📍 Denver📍 New Haven GV20 Therapeutics · Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®] Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites📍 Iowa City📍 Boston📍 Royal Oak Novartis Pharmaceuticals · Tests: 225Ac-ETN029, 111In-ETN029 Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung NCT05058651Phase 2, Phase 3265 sites📍 Anchorage📍 Phoenix📍 Phoenix National Cancer Institute (NCI) · Tests: Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors NCT07070232Phase 1, Phase 277 sites📍 Phoenix📍 San Francisco📍 Hartford BioNTech SE · Tests: BNT326, Pumitamig, Itraconazole, Paroxetine A Study of DXC014 in Patients With Advanced Solid Tumors. NCT07177937Phase 15 sites📍 Beijing📍 Changsha📍 Nanchang Hangzhou DAC Biotechnology Co., Ltd. · Tests: DXC014 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors NCT07760012NA1 site📍 Beijing Peking University Third Hospital · Tests: 68Ga-SorB PET/CT Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer NCT05522660Phase 315 sites📍 Naples📍 Padova📍 Perugia ETOP IBCSG Partners Foundation · Tests: Stereotactic radiosurgery, Immune checkpoint inhibitor
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy